A Clinical Study of TQC2731 Injection in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Inclusion Criteria: * Able and willing to provide written informed consent and comply with the study protocol; * Participant must be ≥40 to ≤80 years of age at the time of signing informed consent. * Participants with a physician diagnosis of Chronic Obstructive Pulmonary Disease(COPD) and a history of COPD ≥12 months with medical records or related records at the time of screening; * Post-bronchodilator FEV1/Forced vital capacity (FVC)\<0.70 and post-bronchodilator FEV1 % predicted ≥20% and \< 80% during screening. * Modified Medical Research Council (mMRC) Dyspnea Scale grade≥2 during screening. * Background triple therapy (ICS+long-acting beta-agonists (LABA)+LAMA) for at least 3 months with a stable dose for at least 1 month prior to randomization; Double therapy allowed if ICS is contraindicated. * With a history of acute exacerbation of ≥2 moderate or ≥1 severe within the previous 12 months prior to screening. Multiple acute exacerbation events with an interval of less than 14 days are counted as one. Exclusion Criteria: * COPD with asthma; * Subjects with active pulmonary diseases other than COPD assessed by the investigator. * Moderate to severe Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) occurred within 4 weeks prior to screening or during screening; * History of lung transplantation; * Previous use of TQC2731. * Diagnosis of alpha-1 anti-trypsin deficiency; * History of lung volume reduction surgery or pneumonectomy within 6 months prior to randomization, or planned lung volume reduction surgery during the study period; * Positive hepatitis B surface antigen, or hepatitis C virus antibody, or syphilis antibody. * Diagnosis of immunodeficiency, including but not limited to HIV infection; * Infection requiring systemic therapy within 2 weeks prior to randomization. * Starting rehabilitation within 4 weeks prior to randomization, or planned rehabilitation during the study period; * Treatment with oxygen of more than 12 hours per day. * Heart failure New York Heart Association (NYHA) class III or IV during the screening period. * History of malignancy within 5 years prior to screening, excluding cervical carcinoma in situ, ductal carcinoma in situ, etc. * Pregnancy or breastfeeding.